These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 31277785)
1. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival? Di Nunno V; Santoni M; Massari F Eur Urol Oncol; 2019 Jul; 2(4):471. PubMed ID: 31277785 [No Abstract] [Full Text] [Related]
2. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768 [TBL] [Abstract][Full Text] [Related]
3. Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. Roviello G; Gatta Michelet MR; D'Angelo A; Nobili S; Mini E Clin Transl Oncol; 2020 Jul; 22(7):1033-1039. PubMed ID: 31617061 [TBL] [Abstract][Full Text] [Related]
4. Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer? Reis LO Eur Urol; 2018 Nov; 74(5):682-683. PubMed ID: 30170874 [No Abstract] [Full Text] [Related]
5. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619 [TBL] [Abstract][Full Text] [Related]
6. [The modern treatment of metastatic castration-resistant prostate cancer]. Küronya Z; Biró K; Maráz A; Géczi L Magy Onkol; 2019 Mar; 63(1):41-50. PubMed ID: 30889620 [TBL] [Abstract][Full Text] [Related]
8. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer. Condon B; Liskaser G; Thangasamy IA; Murphy DG Curr Opin Urol; 2020 Jul; 30(4):620-622. PubMed ID: 31725005 [No Abstract] [Full Text] [Related]
10. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511 [TBL] [Abstract][Full Text] [Related]
12. [Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies]. Berlin A; Fernández MI Rev Med Chil; 2015 Feb; 143(2):223-36. PubMed ID: 25860365 [TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective. Huang PC; Huang LH; Yang CK; Li JR; Chen CS; Wang SS; Chiu KY; Ou YC; Lin CY PLoS One; 2024; 19(8):e0306900. PubMed ID: 39110673 [TBL] [Abstract][Full Text] [Related]
14. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer? Albiges L; Loriot Y; Massard C; Fizazi K Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192 [No Abstract] [Full Text] [Related]
15. Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer. Rhea LP; Gupta B; Aragon-Ching JB Asian J Androl; 2019; 21(2):107-108. PubMed ID: 30460933 [TBL] [Abstract][Full Text] [Related]
17. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354 [TBL] [Abstract][Full Text] [Related]
18. An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer. Brave M; Weinstock C; Brewer JR; Chi DC; Suzman DL; Cheng J; Zhang L; Sridhara R; Ibrahim A; Kluetz PG; Pazdur R; Beaver JA Clin Cancer Res; 2020 Sep; 26(18):4717-4722. PubMed ID: 32284318 [TBL] [Abstract][Full Text] [Related]
19. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer. Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086 [TBL] [Abstract][Full Text] [Related]
20. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. Bambury RM; Rathkopf DE Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]